Saruparib in combination with androgen receptor pathway inhibitors in metastatic hormone-sensitive prostate cancer: EvoPAR-Prostate01
{{output}}
Poly(ADP-ribose) polymerase (PARP) inhibitor plus androgen receptor pathway inhibitor (ARPI) is approved for selected patients with metastatic castration-resistant prostate cancer. Saruparib (AZD5305) is a new-generation PARP inhibitor that selectively inhibit... ...
